<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc041122.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2004

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 22 November,2004  By /s/Ronald Lea Erratt Company Secretary

ASX MEDIA RELEASE
22 NOVEMBER, 2004

GLYCOTEX INC RECEIVES ADDITIONAL CAPITAL FOR THE DEVELOPMENT
OF GLUCOPRIME.

Novogen Limited (ASX: NRT - Nasdaq: NVGN) today announced that
Glycotex, Inc., its US based subsidiary, had received an
additional A$900,000 from the exercise of outstanding
shareholder warrants.  Subsequent to this issue of further
shares, Novogen will retain 93% of Glycotex, Inc.

Glycotex, Inc., holds a licence from Novogen Limited
for the development of its Glucan technology.

Glycotex, Inc., is conducting a phase II clinical trial
in Australia on the Glucan product "Glucoprime".

Glucoprime is based on Novogen's Glucan technology which
is a carbohydrate-based drug designed to stimulate wound
healing in skin ulcers in which the normal healing process
is delayed. This includes ulcers due to diabetes, bed-sores,
arterial disease, and poor circulation.

The double-blind, placebo controlled phase II trial is
being conducted on patients with chronic deep venous
stasis ulcers of the legs.

Venous insufficiency ulcers are the most common form of
skin ulcer in the community, and the problem is a major
community health issue.

The proceeds of the warrants will allow the Company to
further pursue its research and development of Glucoprime
and for general corporate purposes.

Further information on Novogen Limited can be found at
www.novogen.com.


Under U.S. law, a new drug cannot be marketed until
it has been investigated in clinical trials and
approved by the FDA as being safe and effective for the
intended use.
Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995.  You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Marshall Edwards, Inc., + 61.2.9878 0088

</TEXT>
</DOCUMENT>
